# TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

> **NCT02186301** · PHASE2,PHASE3 · TERMINATED · sponsor: **Clovis Oncology, Inc.** · enrollment: 100 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Rociletinib Mono-Therapy
- **DRUG:** Erlotinib Mono-Therapy

## Key facts

- **NCT ID:** NCT02186301
- **Lead sponsor:** Clovis Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11
- **Primary completion:** 2017-06-28
- **Final completion:** 2017-06-28
- **Target enrollment:** 100 (ACTUAL)
- **Why stopped:** Sponsor discontinued development of CO-1686 for NSCLC
- **Last updated:** 2019-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02186301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02186301, "TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02186301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*